A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder

Phase 4CompletedNCT00191061

Eli Lilly and Company640 enrolled

Overview

The purpose of this study is to compare the tolerability and efficacy of different doses of duloxetine in patients with major depressive disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

640

Conditions

Depressive Disorder

Interventions

duloxetine hydrochlorideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients at least 18 years of age (male and/or female) who meet criteria for major depressive disorder (MDD) as defined by the Diagnostic and Statistical Manual for Mental Disorders Fourth Edition Text Revision (DSM-IV-TR). Patients may have comorbid Anxiety Disorders, except for Obsessive Compulsive Disorder * Tests negative for pregnancy at the time of enrollment based on a serum pregnancy test and agrees to use a reliable method of birth control (for example, use of oral contraceptives or Norplant a reliable barrier method of birth control diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) during the study and for 1 month following the last dose of study drug. * Hamilton Depression Rating 17 Item Scale (HAMD-17) greater than 15 at Visits 1 and 2. Exclusion Criteria: * Have any current Axis I disorder other than major depressive disorder (MDD), dysthymia, or any anxiety disorder; however, obsessive-compulsive disorder is excluded. * Have any previous or current diagnosis of bipolar disorder, obsessive-compulsive disorder, schizophrenia, or other psychotic disorders. * Lack of response of the current episode of major depression to two or more adequate courses of antidepressant therapy at clinically appropriate dose for a minimum of 4 weeks or, in the judgment of the investigator, the patient meets criteria for treatment-resistant depression. * DSM-IV-TR-defined history of substance abuse or dependence within the past 6 months, excluding nicotine and caffeine. * Patients judged to be at serious suicidal risk in the opinion of the investigator.

Locations (32)

Outcomes

Primary Outcomes

The primary objective in the acute phase of this study is to compare the incidence of treatment-emergent nausea

for patients initially dosed at duloxetine 30 mg QD

(once-daily), versus duloxetine 60 mg QD.

The primary objective in the extension phase of this study is to compare efficacy in patients not meeting response criteria during the acute phase for patients dosed at duloxetine 60 mg QD versus duloxetine 120 mg QD.

Secondary Outcomes

The secondary objective of greatest importance is to compare the incidence of treatment-emergent nausea

(as defined for the primary objective) for patients

initially dosed at duloxetine 30 mg QD, versus duloxetine 30 mg BID (twice-daily).

Additional secondary objectives include comparing the three initial dosing groups in regards to:Mean changes from baseline in the category total scores and individual items scores of the AMDP-5

The incidence and severity of adverse events using rates of spontaneously reported treatment-emergent adverse events, rates of discontinuations due to

adverse events, categorical changes in AMDP-5 items, mean changes and categorical changes in vital signs

as well as mean changes and rates of abnormal laboratory analytes

Mean changes from baseline in the HAMD17 total score, HAMD subscales, HAMD17 individual items, 30-item Inventory of Depressive Symptoms,

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Little Rock, Arkansas, United States

Coral Springs, Florida, United States

Jacksonville, Florida, United States

Miami, Florida, United States

Port Charlotte, Florida, United States

Boise, Idaho, United States

Edwardsville, Illinois, United States

Lafayette, Indiana, United States

Terre Haute, Indiana, United States

Metairie, Louisiana, United States

...and 22 more locations